[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6231035A2 - Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico - Google Patents

Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico

Info

Publication number
CO6231035A2
CO6231035A2 CO09065607A CO09065607A CO6231035A2 CO 6231035 A2 CO6231035 A2 CO 6231035A2 CO 09065607 A CO09065607 A CO 09065607A CO 09065607 A CO09065607 A CO 09065607A CO 6231035 A2 CO6231035 A2 CO 6231035A2
Authority
CO
Colombia
Prior art keywords
group
optionally substituted
formula
represented
compound
Prior art date
Application number
CO09065607A
Other languages
English (en)
Inventor
Takanobu Kuroita
Hiroki Sakamoto
Hideyuki Igawa
Minoru Sasaki
Kouchei Asano
Tsuyoshi Maekawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6231035A2 publication Critical patent/CO6231035A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Un compuesto representado por la siguiente fórmula (I):en donde R1 es (1) un grupo oxo; (2) un grupo tioxo; (3) un grupo representado por la fórmula: =N-R en donde R es (i) un grupo C1-C6 alquilo opcionalmente substituido; (ii) un grupo C3-C6 cicloalquilo opcionalmente substituido; (iii) un grupo representado por la fórmula: -O-Ra en donde Ra es hidrógeno, un grupo C1-C6 alquilo opcionalmente substituido o un grupo C3-C6 cicloalquilo opcionalmente substituido; o (iv) un grupo representado por la fórmula: -N(Rb)-Rc en donde Rb y Rc cada uno son independientemente hidrógeno, un grupo C1-C6 alquilo opcionalmente substituido o un grupo C3-C6 cicloalquilo opcionalmente substituido, o Rb y Rc se unen entre si para formar, junto con el átomo de nitrógeno enlazado al mismo, un grupo heterocíclico que contiene nitrógeno opcionalmente substituido; (4) un grupo representado por la fórmula: =N-CO-R' en donde R' es un grupo C1-C6 alquilo opcionalmente substituido o un grupo cíclico opcionalmente substituido; (5) un grupo representado por la fórmula: =N-CO-OR' en donde R' es como se definió anteriormente; o (6) un grupo representado por la fórmula: =N-SO2-R' en donde R' es como se definió anteriormente; y un grupo representado por la fórmula:esen donde ...
CO09065607A 2006-11-24 2009-06-24 Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico CO6231035A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006317839 2006-11-24
JP2007232106 2007-09-06

Publications (1)

Publication Number Publication Date
CO6231035A2 true CO6231035A2 (es) 2010-12-20

Family

ID=39205144

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09065607A CO6231035A2 (es) 2006-11-24 2009-06-24 Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico

Country Status (21)

Country Link
US (2) US20080207654A1 (es)
EP (2) EP2074117A2 (es)
JP (1) JP2010510962A (es)
KR (1) KR20090085117A (es)
AR (1) AR063912A1 (es)
AU (1) AU2007322608A1 (es)
BR (1) BRPI0719060A2 (es)
CA (1) CA2670404A1 (es)
CL (1) CL2007003352A1 (es)
CO (1) CO6231035A2 (es)
CR (1) CR10847A (es)
EA (1) EA200970510A1 (es)
EC (1) ECSP099461A (es)
IL (1) IL198819A0 (es)
MA (1) MA30985B1 (es)
MX (1) MX2009005449A (es)
NO (1) NO20092415L (es)
PE (1) PE20081228A1 (es)
TN (1) TN2009000199A1 (es)
TW (1) TW200829581A (es)
WO (1) WO2008062905A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7103906B1 (en) 2000-09-29 2006-09-05 International Business Machines Corporation User controlled multi-device media-on-demand system
JP2004511937A (ja) 2000-10-11 2004-04-15 ユナイテッド　ビデオ　プロパティーズ，　インコーポレイテッド オン−デマンドメディア送達システムのサーバにおけるデータの格納を提供するシステムおよび方法
US8086575B2 (en) 2004-09-23 2011-12-27 Rovi Solutions Corporation Methods and apparatus for integrating disparate media formats in a networked media system
US9681105B2 (en) 2005-12-29 2017-06-13 Rovi Guides, Inc. Interactive media guidance system having multiple devices
US8607287B2 (en) 2005-12-29 2013-12-10 United Video Properties, Inc. Interactive media guidance system having multiple devices
WO2008062905A2 (en) * 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
US20090019492A1 (en) 2007-07-11 2009-01-15 United Video Properties, Inc. Systems and methods for mirroring and transcoding media content
EP2384327B1 (en) 2009-01-30 2013-07-31 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
JPWO2010095462A1 (ja) 2009-02-23 2012-08-23 興和株式会社 新規な３−（５−アルコキシピリミジン−２−イル）ピリミジン−４（３ｈ）−オン構造を有する化合物及びこれを含有する医薬
EP2420501A4 (en) * 2009-04-17 2012-08-29 Kowa Co NEW COMPOUNDS WITH 3-HETEROARYLPYRIMIDIN-4- (3H) -ONE STRUCTURE AND PHARMACEUTICAL PREPARATION THEREWITH
EP2436675A1 (en) 2009-05-29 2012-04-04 Kowa Company, Ltd. Novel -phenoxybenzeneacetic acid derivative and pharmaceutical preparation comprising same
WO2011024468A1 (ja) 2009-08-27 2011-03-03 興和株式会社 新規なスルホンアミド誘導体及びこれを含有する医薬
US9014546B2 (en) 2009-09-23 2015-04-21 Rovi Guides, Inc. Systems and methods for automatically detecting users within detection regions of media devices
TWI500611B (zh) * 2009-09-29 2015-09-21 Kowa Co 新穎苯基吡啶衍生物及含有該衍生物之醫藥
JPWO2011077711A1 (ja) * 2009-12-22 2013-05-02 興和株式会社 新規な２−ピリドン誘導体及びこれを含有する医薬
JPWO2011105099A1 (ja) * 2010-02-25 2013-06-20 興和株式会社 新規な４−アルコキシピリミジン構造を有する化合物及びこれを含有する医薬
AU2011251302A1 (en) * 2010-05-11 2013-01-10 8337187 Canada, Inc. Benzo- or pyrido-imidazole derivative
JPWO2012011592A1 (ja) * 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
NZ608499A (en) 2010-10-07 2015-03-27 Takeda Pharmaceutical 1,4-oxazepane derivatives
WO2012078673A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
WO2012078684A1 (en) 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyridinone-pyridinyl compounds
US8507499B2 (en) 2010-12-06 2013-08-13 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
ES2562994T3 (es) * 2011-03-14 2016-03-09 Kowa Company Ltd. Nuevo derivado de fenilpiridina y medicamento que contiene el mismo
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9056110B2 (en) 2011-12-06 2015-06-16 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
PL2794597T3 (pl) * 2011-12-21 2018-03-30 Ono Pharmaceutical Co., Ltd. Pochodne pirydynonu i pirymidynonu jako inhibitory czynnika xia
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
HUE054178T2 (hu) 2013-06-07 2021-08-30 Aclaris Therapeutics Inc Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek
US9981928B2 (en) 2013-06-20 2018-05-29 Bayer Cropscience Aktiengesellschaft Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides
JP2016526539A (ja) 2013-06-20 2016-09-05 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体
US9674563B2 (en) 2013-11-04 2017-06-06 Rovi Guides, Inc. Systems and methods for recommending content
EP3083584B1 (en) 2013-12-19 2018-02-21 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in the treatment of tissue fibrosis
RU2693622C2 (ru) 2014-04-01 2019-07-03 Мерк Шарп И Доум Корп. Пролекарственные средства ингибиторов обратной транскриптазы вич
US10065955B2 (en) 2014-12-10 2018-09-04 Ono Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
KR20190028763A (ko) 2016-07-12 2019-03-19 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 바이시클릭 화합물
KR101984121B1 (ko) * 2017-08-21 2019-05-30 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
IL296054A (en) 2020-03-27 2022-10-01 Aclaris Therapeutics Inc Oral preparations of the mk2 pathway inhibitor for the treatment of immune conditions
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411980A (en) * 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
JPH03218371A (ja) 1989-08-02 1991-09-25 Takeda Chem Ind Ltd ピラゾール誘導体
DE69013607T2 (de) * 1989-08-02 1995-03-02 Takeda Chemical Industries Ltd Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
JP3032844B2 (ja) 1990-02-15 2000-04-17 武田薬品工業株式会社 ピリミジンジオン誘導体
CA2036304C (en) * 1990-02-15 2001-04-17 Takehiko Naka Pyrimidinedione derivatives, their production and use
JP3114073B2 (ja) 1990-03-07 2000-12-04 武田薬品工業株式会社 アンジオテンシンｉｉ拮抗薬−含窒素異項環化合物
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5166206A (en) * 1990-03-30 1992-11-24 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
US5472967A (en) * 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
ATE264323T1 (de) * 1992-09-14 2004-04-15 Takeda Chemical Industries Ltd Heterocyclische verbindungen und ihre verwendung als angiotensin ii antagonisten
JPH06239859A (ja) 1992-09-14 1994-08-30 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する環状化合物およびその用途
JP3412887B2 (ja) 1992-12-22 2003-06-03 武田薬品工業株式会社 アンギオテンシンｉｉ拮抗作用を有する複素環化合物およびその用途
EP0603712B1 (en) * 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
US20010020100A1 (en) * 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
US7179823B1 (en) 1999-11-10 2007-02-20 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
CN1441794A (zh) 2000-07-13 2003-09-10 武田药品工业株式会社 富脂质斑退化剂
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
NZ533893A (en) 2002-01-11 2006-06-30 Takeda Pharmaceutical Coumarin derivatives, process for their production and use thereof
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
WO2008062905A2 (en) * 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof

Also Published As

Publication number Publication date
EP2074117A2 (en) 2009-07-01
EA200970510A1 (ru) 2009-12-30
TW200829581A (en) 2008-07-16
BRPI0719060A2 (pt) 2014-02-04
AR063912A1 (es) 2009-02-25
JP2010510962A (ja) 2010-04-08
US20080207654A1 (en) 2008-08-28
EP2256115A1 (en) 2010-12-01
CA2670404A1 (en) 2008-05-29
AU2007322608A1 (en) 2008-05-29
US20100056526A1 (en) 2010-03-04
NO20092415L (no) 2009-08-17
PE20081228A1 (es) 2008-10-29
WO2008062905A3 (en) 2008-12-04
WO2008062905A2 (en) 2008-05-29
CL2007003352A1 (es) 2008-07-04
AU2007322608A2 (en) 2009-07-16
KR20090085117A (ko) 2009-08-06
MX2009005449A (es) 2009-06-02
TN2009000199A1 (en) 2010-10-18
IL198819A0 (en) 2010-02-17
MA30985B1 (fr) 2009-12-01
CR10847A (es) 2009-07-13
ECSP099461A (es) 2009-11-30

Similar Documents

Publication Publication Date Title
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
PE20090897A1 (es) Compuestos de biciclolactama sustituida como inhibidores de la enzima dgat-1
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
DOP2011000061A (es) Compuestos de pirrol
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
AR058404A1 (es) Derivados diamina como inhibidores de leucotrieno a4 hidrolasa
ECSP10010060A (es) Derivados de pirazol sustituídos
PE20130155A1 (es) Derivados de ariletinilo
TW201129556A (en) Novel antiplatelet agent
MY154772A (en) Harmful arthropod control composition, and fused heterocyclic compound
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
AR075084A1 (es) Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
TW200736363A (en) Material for organic electroluminescent device and organic electroluminescent device
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
ES2590504T3 (es) N-ciclilamidas como nematicidas
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
ES2571327T3 (es) Composiciones plaguicidas
CO6160266A2 (es) Derivado de oxopirazina y herbicida
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
TW200722422A (en) Heterocyclic compound and organic electroluminescent device using the same
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.

Legal Events

Date Code Title Description
FA Application withdrawn